20.500.12556/DKUM-88498 Kakovost življenja bolnika z rakom ščitnice po terapiji z radioaktivnim jodom Quality of life of a thyroid cancer patient after radioactive iodine therapy Uvod: Rak ščitnice je najpogostejša maligna bolezen endokrinega sistema. Pri večini bolnikov z rakom ščitnice se opravi tiroidektomija ali odstranitev ščitnice, po kateri bolniki največkrat še prejemajo radioaktivni jod. Namen zaključnega dela je raziskati, s kakšnimi težavami se srečujejo bolniki po terapiji z radioaktivnim jodom in kakšna je njihova kakovost življenja. Metode: Izvedli smo pregled znanstvene literature na temo kakovost življenja bolnika z rakom ščitnice po terapiji z radioaktivnim jodom, z upoštevanjem določenih vključitvenih in izključitvenih kriterijev. Uporabili smo deskriptivno metodo dela. Analizo zbranih raziskav smo predstavili v obliki evalvacijske tabele ter sintezo zbranih podatkov izvedli s pomočjo vsebinske analize. Rezultati: V končno analizo smo vključili pet raziskav. Najpogostejše težave in omejitve pri bolnikih z rakom ščitnice, ki so bili zdravljeni z radioaktivnim jodom, so bile depresija, diareja, kserostomija, disfagija, težave z dihanjem, bolečine in utrujenost. Ugotovili smo, da alopecija predstavlja najmanjšo težavo pri bolnikih, ki so prejeli terapijo z radioaktivnim jodom. Razprava in zaključek: Po obsevanju bolnika z določenimi odmerki radioaktivnega joda je pomembno, da v domačem okolju bolnik upošteva navodila samoizolacije. Zdravljenje z radioaktivnim jodom izboljša preživetje bolnikov in omogoča dolgoletno preživetje ter kljub neželenim učinkom med in po zdravljenju dolgoročno pozitivno vpliva na kakovost življenja bolnikov. Introduction: Thyroid cancer is the most prevalent type of cancer that affects the endocrine system. Typically, patients diagnosed with thyroid cancer undergo thyroidectomy, which involves the removal of the thyroid gland. After the gland removal, most patients opt for radioactive iodine therapy. As part of this study, the objective is to examine the challenges patients encounter after undergoing radioactive iodine therapy and their overall quality of life. Methods: Our study delved into the scientific literature on the quality of life experienced by patients who received radioactive iodine therapy for thyroid cancer, and we employed specific criteria to determine which studies to incorporate. Our methodology was descriptive, and we conveyed the results through an assessment table and a summary of our discoveries. Additionally, we conducted content analysis to obtain a more comprehensive understanding of the data. Results: A thorough analysis of five studies has identified common issues and limitations that thyroid cancer patients may experience during radioactive iodine treatment. Among the most frequently reported concerns are depression, diarrhea, xerostomia, dysphagia, respiratory problems, pain, and fatigue. Interestingly, alopecia appears to be the least problematic side effect reported by patients who underwent radioactive iodine therapy. Discussion and conclusion: Upon receiving specific doses of radioactive iodine, patients must follow self-isolation guidelines at home. This treatment is beneficial in enhancing patient survival rates and enabling a longer life span. While there may be unfavorable effects during and after the treatment process, the overall positive impact on the patients well-being makes it a valuable choice. rak ščitnice kakovost življenja radioaktivni jod thyroid cancer quality of life radioactive iodine true false false [L. Vodušek] Slovenski jezik Angleški jezik Diplomsko delo/naloga 2024-05-07 10:10:32 2024-07-04 11:46:13 2024-07-05 04:13:26 0000-00-00 00:00:00 2024 0 Maribor 0 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006+612.44:615.849(043.2) 200591875 VS_Vodusek_Lea_2024.pdf VS_Vodusek_Lea_2024.pdf 1 E3CF90FAD8BB886923CD7193FDA1B1A0 7262c3de61b097a63bdbd332b3b5da275e2998d19379adbb383bad09c321407a 5675d425-3936-11ef-ad11-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=181057 Fakulteta za zdravstvene vede 0 0 0